Papers

Single or multiple daily doses of aminoglycosides: a meta- analysis

^a Division of Geographic Medicine and Infectious Diseases, New England Medical Center Hospitals, Tufts University School of Medicine, Boston, MA 02111, USA, ^b Division of Clinical Care Research, New England Medical Center Hospitals, Tufts University School of Medicine

Correspondence to: Dr Barza.

Abstract

Objective: To assess relative efficacy and toxicity of aminoglycosides given by single daily dose compared with multiple daily doses.
Design: Meta-analysis of 21 randomised trials identified through MEDLARS (1966 to January 1995). Data were overviewed with fixed effects and random effects models and with meta-regression analysis.
Subjects: Total of 3091 patients with bacterial infection, most without pre-existing renal disease.
Interventions: Patients were randomised to receive aminoglycosides once daily or multiple times daily with similar total daily dose.
Main outcome measures: Clinical failure of treatment, nephrotoxicity, ototoxicity, and mortality.
Results: Single daily dose regimen produced a non-significant decrease in risk of antibiotic failures (random effects risk ratio 0.83 (95% confidence interval 0.57 to 1.21)). Benefit of once daily dosing was greater when the percentage of pseudomonas isolates in a trial was larger. Once daily administration reduced risk of nephrotoxicity (fixed effects risk ratio 0.74 (0.54 to 1.00)). Similar trends were noted for patients with febrile neutropenia and for children. There was no significant difference in ototoxicity between the two dosing regimens, but the power of the pooled trials to detect a meaningful difference was low. There was no significant difference in mortality.
Conclusions: Once daily administration of aminoglycosides in patients without pre-existing renal impairment is as effective as multiple daily dosing, has a lower risk of nephrotoxicity, and no greater risk of ototoxicity. Given the additional convenience and reduced cost, once daily dosing should be the preferred mode of administration.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

This article has been cited by other articles:

• Selby, N. M., Shaw, S., Woodier, N., Fluck, R. J., Kolhe, N. V. (2009). Gentamicin-associated acute kidney injury. QJM 102: 873-880 [Abstract] [Full text]  
• Flume, P. A., Mogayzel, P. J. Jr., Robinson, K. A., Goss, C. H., Rosenblatt, R. L., Kuhn, R. J., Marshall, B. C., and the Clinical Practice Guidelines for Pulmonary, (2009). Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. Am. J. Respir. Crit. Care Med. 180: 802-808 [Abstract] [Full text]  
• Leibovici, L., Vidal, L., Paul, M. (2009). Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 63: 246-251 [Abstract] [Full text]  
• Ariano, R. E, Zelenitsky, S. A, Kassum, D. A (2008). Aminoglycoside-Induced Vestibular Injury: Maintaining a Sense of Balance. The Annals of Pharmacotherapy 42: 1282-1289 [Abstract] [Full text]  
• (2007). Is a once daily dose of gentamicin safe and effective in the treatment of uti in infants and children?. Arch. Dis. Child. 92: 823-824 [Full text]  
• Venkataraman, R., Kellum, J. A. (2007). Prevention of Acute Renal Failure. Chest 131: 300-308 [Abstract] [Full text]  
• Zahar, J.-R., Rioux, C., Girou, E., Hulin, A., Sauve, C., Bernier-Combes, A., Brun-Buisson, C., Lesprit, P. (2006). Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother 58: 651-656 [Abstract] [Full text]  
• Mulheran, M., Hyman-Taylor, P., Tan, K. H.-V., Lewis, S., Stableforth, D., Knox, A., Smyth, A. (2006). Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients.. Antimicrob. Agents Chemother. 50: 2293-2299 [Abstract] [Full text]  
• Khan, A. M., Ahmed, T., Alam, N. H., Chowdhury, A. K., Fuchs, G. J. (2006). Extended-Interval Gentamicin Administration in Malnourished Children. J Trop Pediatr 52: 179-184 [Abstract] [Full text]  
• Nestaas, E, Bangstad, H-J, Sandvik, L, Wathne, K-O (2005). Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch. Dis. Child. Fetal Neonatal Ed. 90: F294-f300 [Abstract] [Full text]  
• Kim, M.-J., Bertino, J. S. Jr., Erb, T. A., Jenkins, P. L., Nafziger, A. N. (2004). Application of Bayes Theorem to Aminoglycoside-Associated Nephrotoxicity: Comparison of Extended-Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple-Daily Dosing. J Clin Pharmacol 44: 696-707 [Abstract] [Full text]  
• English, M, Mohammed, S, Ross, A, Ndirangu, S, Kokwaro, G, Shann, F, Marsh, K (2004). A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants. Arch. Dis. Child. 89: 665-669 [Abstract] [Full text]  
• Contopoulos-Ioannidis, D. G., Giotis, N. D., Baliatsa, D. V., Ioannidis, J. P. A. (2004). Extended-Interval Aminoglycoside Administration for Children: A Meta-analysis. Pediatrics 114: e111-e118 [Abstract] [Full text]  
• Graham, A C., Mercier, R.-C., Achusim, L. E, Pai, M. P (2004). Extended-Interval Aminoglycoside Dosing for Treatment of Enterococcal and Staphylococcal Osteomyelitis. The Annals of Pharmacotherapy 38: 936-941 [Abstract] [Full text]  
• Sung, L., Dupuis, L. L., Bliss, B., Taddio, A., Abdolell, M., Allen, U., Rolland, M., Tong, A., Taylor, T., Doyle, J. (2003). Randomized Controlled Trial of Once- Versus Thrice-Daily Tobramycin in Febrile Neutropenic Children Undergoing Stem Cell Transplantation. JNCI J Natl Cancer Inst 95: 1869-1877 [Abstract] [Full text]  
• Tan, K. H.-V., Mulheran, M., Knox, A. J., Smyth, A. R. (2003). Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 167: 819-823 [Full text]  
• Dotan, Z. A., Hana, R., Simon, D., Geva, D., Pfeffermann, R. A., Ezri, T. (2003). The Effect of Vecuronium Is Enhanced by a Large Rather than a Modest Dose of Gentamicin as Compared with No Preoperative Gentamicin. Anesth. Analg. 96: 750-754 [Abstract] [Full text]  
• Baciewicz, A. M, Sokos, D. R, Cowan, R. I (2003). Aminoglycoside-Associated Nephrotoxicity in the Elderly. The Annals of Pharmacotherapy 37: 182-186 [Abstract] [Full text]  
• Aminimanizani, A., Beringer, P. M., Kang, J., Tsang, L., Jelliffe, R. W., Shapiro, B. J. (2002). Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 50: 553-559 [Abstract] [Full text]  
• Raveh, D., Kopyt, M., Hite, Y., Rudensky, B., Sonnenblick, M., Yinnon, A.M. (2002). Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 95: 291-297 [Abstract] [Full text]  
• Fish, D. N. (2002). Extended-Interval Dosing of Aminoglycoside Antibiotics in Critically Ill Patients. Journal of Pharmacy Practice 15: 85-95 [Abstract]  
• Whitehead, A., Conway, S.P., Etherington, C., Caldwell, N.A., Setchfield, N., Bogle, S. (2002). Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 19: 303-309 [Abstract] [Full text]  
• BLOCK, C. A., MANNING, H. L. (2002). Prevention of Acute Renal Failure in the Critically Ill. Am. J. Respir. Crit. Care Med. 165: 320-324 [Full text]  
• Chattopadhyay, B. (2002). Newborns and gentamicin--how much and how often?. J Antimicrob Chemother 49: 13-16 [Full text]  
• TAN, K, SMYTH, A (2001). Commentaries{---}read with caution!. Arch. Dis. Child. 85: 268b-268 [Full text]  
• Hoffken, G., Pasold, R., Pfluger, K. H., Finke, J., Fauser, A. A., Szelenyi, H., Wagner, J. (1999). An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. J Antimicrob Chemother 44: 367-376 [Abstract] [Full text]  
• Rybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A., Drusano, G. L. (1999). Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity. Antimicrob. Agents Chemother. 43: 1549-1555 [Abstract] [Full text]  
• Lundergan, F. S., Kim, E. H., Cohen, R. S. (1999). Once-daily Gentamicin Dosing in Newborn Infants. Pediatrics 103: 1228-1234 [Abstract] [Full text]  
• Mingeot-Leclercq, M.-P., Tulkens, P. M. (1999). Aminoglycosides: Nephrotoxicity. Antimicrob. Agents Chemother. 43: 1003-1012 [Full text]  
• LeBrun, M., Grenier, L., Gourde, P., Bergeron, M. G., Labrecque, G., Beauchamp, D. (1999). Effectiveness and Toxicity of Gentamicin in an Experimental Model of Pyelonephritis: Effect of the Time of Administration. Antimicrob. Agents Chemother. 43: 1020-1026 [Abstract] [Full text]  
• Jaspers, C. A. J. J., Kieft, H., Speelberg, B., Buiting, A., van Marwijk Kooij, M., Ruys, G. J. H. M., Vincent, H. H., Vermeulen, M. C. A., Olink, A. G., Hoepelman, I. M. (1998). Meropenem versus Cefuroxime plus Gentamicin for Treatment of Serious Infections in Elderly Patients. Antimicrob. Agents Chemother. 42: 1233-1238 [Abstract] [Full text]  
• (1997). Aminoglycosides once daily?. DTB 35: 36-37 [Abstract] [Full text]  
• Campbell, H. (1996). Single or multiple daily doses of aminoglycosides. BMJ 313: 490-490 [Full text]  
• Begg, E. J, Duffull, S. B, Kirlpatrick, C. M (1996). Exposure to aminoglycosides should be monitored during treatment. BMJ 313: 491-491 [Full text]  
• Cooke, R P D, Grace, R J, Gover, P A (1996). Giving gentamicin once daily for neutropenic fever has proved to be simple. BMJ 313: 490a-490 [Full text]  
• (1996). A GOOD DOSING FREQUENCY FOR AMINOGLYCOSIDES. JWatch General 1996: 1-1 [Full text]  

Rapid Responses:

Read all Rapid Responses

When is the most appropriate time to collect levels?

Fungisai Mugwagwa
bmj.com, 11 Feb 2009 [Full text]